We found that the luminal and luminal-HER2-positive breast cancers are more likely to be detected in screening than the TNBC and the HER2 positive breast cancers which is similar as reported in registry-based cohort studies with women screened between 40 and 70 in Asian, European and North American countries [13,14,15,32]. The gene discussed is ERBB2; the disease is breast carcinoma.